Specialties & Topics
- Arthritis/Rheumatic Disease
- Breast Cancer
- GERD/Peptic Ulcers
An ongoing dialogue on HIV/AIDS, infectious diseases,
September 18th, 2009
Integrase Inhibitors: In Search of an Abbreviation
The alphabet soup that characterizes HIV therapeutics has always been one of its quirky challenges — for example, who could possibly know that 3TC, CBV, TZV, EPZ, and LAM all refer to drugs that are (or contain) lamivudine?
This drives our ID fellows nuts, and is certainly a strong deterrent to non-HIV specialists to learning the field.
(Maybe that’s why they pay us the big bucks… oh wait.)
And while we’ve grown comfortable with the abbreviations for the 3 oldest drug classes — NRTI, NNRTI, and PI — what are we to do with integrase inhibitors? Some candidates:
- “II” — sounds funny when you say it (“eye-eye”), and could be confused with “eleven” depending on the font
- “INSTI” — for “integrase strand transfer inhibitor”; I’ve already seen this one around a lot, but have also seen it written “InSTI” (lower-case n), which is hard to type
- “INI” — for “INtegrase Inhibitor”; same upper vs lower-case issue as “INSTI”, and saying “INI” always has an anatomic (especially umbilical) connotation to it
Still not sure where we’ll end up with this one, but I suspect “INSTI” will rule the day.
Leave a Reply
Paul E. Sax, MD
Learn more about HIV and ID Observations.
- It’s Time to Dump the HIV Western Blot
- Anti-Vaccine Movement Slammed By Daily Show; ID Doctors, Pediatricians Happy
- CROI 2015 Dates Announced — And Warning, It’s Still Winter in Boston
- Some ID Stuff We’re Talking About on Rounds
- Simeprevir and (Especially) Sofosbuvir Are Great Leaps Forward — and They Will Cost Plenty
- When Is Vancomycin Nephrotoxic in Critically Ill Patients?
- Novel Antiviral Therapy for RSV Infection (FREE)
- Adjunctive Bedaquiline and Multidrug-Resistant Tuberculosis
- Chikungunya Vaccine Immunogenic and Safe in a Phase I Trial (FREE)
- How Long Should Febrile Infants Be Observed After Blood Culture Collection?
Physician's First WatchToday's breaking medical news